Management of aplastic anemia after failure of frontline immunosuppression
Journal Title:
Expert Review of Hematology
Original Publication Date:
Jul 2019
Bone Marrow Disease(s):
Hypomethylating agents (HMAs) are the standard of care for patients with myelodysplastic syndrome (MDS). However, only around 50% of patients respond to these agents, and responses tend to be transient, with loss of response frequently happening within 2 years and being associated with very poor prognosis and limited therapeutic options. Identification of patients who will respond to HMAs is challenging. Mechanisms underlying resistance to HMAs are not clear yet.
Improved success of HLA-matched unrelated donor (MUD) hematopoietic stem cell transplantation (HCT) for severe